View article in Colorado Real Estate Journal.
Demand for health and life sciences commercial real estate (CRE) is rising, fueled by an aging population and significant advances in biotechnology. However, not all assets in this category are created equal. Investors and lenders must differentiate between specialized property types when underwriting loans and assessing repayment risk. Repayment confidence is typically driven by tenant strength, which depends on the asset’s stability and the economic performance of its underlying industry.
The Health Segment, also referred to as Medical, Healthcare Services, or Clinical Infrastructure, includes facilities that support direct patient care. Demand for healthcare-related CRE is increasing due to demographic aging, rising rates of chronic health conditions, and expanded access to healthcare. This sector spans both public health systems and private providers, offering services such as outpatient care, specialty clinics (e.g., cardiology, oncology, orthopedics), surgery centers, urgent care, behavioral health and rehabilitation, diagnostics and imaging, and health IT, including electronic health records (EHR). Key economic drivers include Medicare and Medicaid expansion, broader insurance coverage, physician group consolidation, hospital affiliations, and a shift toward decentralized, cost-effective/value-based, and preventive care models. Property types largely include medical office buildings (MOBs), outpatient centers, and specialty clinics. These commonly feature high occupancy and stable income, attracting investors seeking their defensive and resilient cash flow.
The Science Segment, also known as Life Sciences, Biotechnology, or the Research & Innovation Economy, is experiencing growing CRE demand, driven by increased research and development (R&D) activity and the commercialization of pharmaceuticals, medical devices, and diagnostics. Typical tenant makeup in this sector includes academic research institutions, biotech firms, and pharmaceutical companies. These tenants require highly specialized facilities such as wet labs and clean rooms, supporting advanced functions such as biotech R&D, clinical trials, drug and vaccine development, genomics, proteomics, diagnostics, advanced therapeutics (cell and gene therapy), biomedical manufacturing, and academic or contract research organizations (CROs). Economic drivers include government and institutional research funding, venture capital, IPO activity, patent cycles, FDA approvals, and rising demand for personalized medicine and biologics. Asset types include wet labs, biomanufacturing facilities, incubators, and research campuses. These buildings often involve significant capital expenditures, custom infrastructure, and feature long lease terms and high tenant retention. However, they carry higher risk due to their specialized, single-use nature and variable tenant credit quality.
Comparative Evaluation Factors
When comparing these two sectors, the following evaluation factors are critical in assessing capital market risk:
- Tenant Risk: Healthcare buildings often feature a diverse mix of private and institutional tenants, including hospitals and large medical groups, typically viewed as stronger credits. Some MOBs may be occupied by smaller physician practices, which can introduce higher risk depending on their specialty. In contrast, many life science tenants are early-stage biotech firms or venture-backed startups with limited balance sheets, contributing to higher perceived risk.
- Lease Profile: Lease structures are generally favorable in both segments, with long-term leases and tenant dependability. However, healthcare assets frequently benefit from a longer renewal history than life science buildings that are more often newer, particularly in emerging markets.
- Market Depth: The healthcare real estate market is considered strong, as it is broad and relatively liquid, contributing to lower overall risk. Life science demand tends to be concentrated in established research hubs, such as Boston or San Diego, with secondary markets presenting slightly riskier investments.
- Reusability: Healthcare spaces offer moderate to high reusability because they can be adapted and leased to new medical specialties. Life science facilities, on the other hand, are highly customized (e.g., wet labs, clean rooms), which makes retrofitting costly and limits their flexibility for alternative uses.
- TI/CapEx Sensitivity: Life science assets have high capital expenditure requirements, commonly ranging from $300 to $800/SF for buildouts. Lenders may need reserve accounts or holdbacks in the budgeting to mitigate the expensive buildout-related risk. Healthcare assets typically have lower TI and CapEx sensitivity.
- Cash Flow Predictability: Healthcare properties offer high cash flow predictability due to steady service demand and proven rent collection. In contrast, the cash flow predictability of life science properties varies from moderate to strong, depending on the age, experience, and financial stability of the tenant.
- Available Loan Terms and Financing Sources: Healthcare assets usually qualify for more favorable terms with a broader range of options from banks, life insurance companies, and CMBS lenders. Life sciences buildings likely require more conservative underwriting with higher repayment risk, shrinking their available group of lenders to select life insurance companies or debt funds with sector experience.
When assessing capital market risk in these sectors, it’s essential to understand the trends and differing dynamics of cash flow stability, tenant quality, and asset flexibility. Healthcare assets are widely regarded as lower-risk, income-stable investments, as they are essential services that produce dependable tenants, demographic resilience, and consistent cash flow. While life science assets present potentially higher returns due to innovation, they are still associated with higher risk from volatility tied to tenant credit, market concentration, and specialized infrastructure. Lastly, life science assets remain sensitive to shifts in funding and political priorities. Potential reductions in federal research budgets, such as cuts to the NIH or NSF, under administrations less supportive of science investment, could impact the viability of early-stage tenants and research-driven facilities.